卡介苗接种对COVID-19发病率、严重程度及临床进展的效力:BCG-REVAC人群分析
基于BCG-REVAC整群随机试验的354403名7至14岁学龄儿童人群,将COVID-19通报病例与试验数据库记录链接,评估出生时接种、学龄期首剂或加强剂卡介苗对COVID-19发病率、重症发生率及临床进展的效力。新生儿剂次和学龄期首剂对重症COVID-19发生率的效力分别为30%(95%CI:1-51)和64%(95%CI:22-84);新生儿剂次对感染者重症临床进展的效力为39%(95%CI:11%-58%)。作者认为学龄期首剂对感染者重症COVID-19发生率有保护作用,新生儿剂次作用较小,学龄期第二剂无作用。
要点
- 新生儿剂次和学龄期首剂对重症COVID-19发生率的效力分别为30%(95%CI:1-51)和64%(95%CI:22-84)。
- 新生儿剂次对COVID-19感染者重症临床进展的效力为39%(95%CI:11%-58%)。
- 作者认为学龄期第二剂对重症COVID-19无作用。
核心结论
- 作者认为,即使学龄期儿童接种和加强接种卡介苗已过去23年,结果仍提示卡介苗首剂对感染者重症COVID-19发生率有保护作用,新生儿剂次作用较小,学龄期第二剂无作用。
研究设计与样本
- 本研究基于BCG-REVAC整群随机试验人群,纳入巴西萨尔瓦多和马瑙斯两市767所学校的354403名7至14岁学龄儿童。
- 研究将传染病通报系统和严重呼吸系统疾病通报系统的COVID-19病例与BCG-REVAC人群进行记录链接,暴露为BCG-REVAC试验中的接种或加强接种。
- 研究结局为COVID-19发病率、重症COVID-19发病率和COVID-19临床进展;项目获巴西巴伊亚联邦大学集体健康研究所伦理委员会批准。
主要发现
- 多变量模型中,新生儿剂次和学龄期首剂对重症COVID-19发生率的效力分别为30%(95%CI:1-51)和64%(95%CI:22-84)。
- 新生儿剂次对COVID-19感染者症状性COVID-19重症临床进展的效力为39%(95%CI:11%-58%)。
- 作者报告学龄期第二剂对重症COVID-19无作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Can vaccination with Bacille Calmette-Guérin prevent clinical progression of COVID-19? Data from the BCG-REVAC trial was archived in a database, creating an excellent opportunity to link it to notified cases of COVID-19 to evaluate the efficacy of BCG against incidence, severity and clinical progression to severe COVID-19 when given at birth day, at school age as a first dose or as a second dose. METHODS: This study was conducted in the population of the BCG-REVAC cluster randomisation trial including 354,403 schoolchildren, aged 7 to 14 years, from 767 schools from two cities, Salvador and Manaus. Cases of COVID-19 from the System for Notification of Infectious Diseases and the System for Notification of Severe Respiratory Illnesses were record linked to BCG-REVAC population. The exposure was Vaccination or revaccination obtained by the BCG-REVAC. The outcomes of interest in this study were incidence COVID-19; incidence of severe COVID-19; and clinical progression of COVID-19. This project was approved by the Ethics Committee of the Institute of Collective Health, Federal University of Bahia, Brazil. RESULTS: The neonatal dose and a first dose of BCG at school age protect against the incidence of severe COVID-19 in multivariate models, whose efficacies were 30 % (95 %CI:1-51) and 64 % (95 %CI: 22-84), respectively. The neonatal dose showed an effect on severe clinical progression of symptomatic COVID-19 disease in COVID-19 infected subjects 39 % (95 %CI:11 % - 58 %). CONCLUSION: Even 23 years after BCG vaccination and revaccination of school-age children our results suggesting a protective effect of BCG first dose against incidence of severe COVID-19 in infected individuals, a smaller effect of the neonatal dose and no effect of the second dose at school age.
引用
- de Souza RA, Barreto FR, de Jesus Lima CCO, et al. Efficacy of BCG vaccination on incidence, severity and clinical progression of COVID-19: A BCG-REVAC population analysis. Vaccine. 2025. PMID: 40058282. doi:10.1016/j.vaccine.2025.126911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。